Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

MEI Pharma Inc
Healthcare
P/NCAV
0.47x
Ticker
MEIP
Exchange
NASDAQ
Country
United States
Close
3.33 $
Mkt Cap
22.2M $
EV
17.0M $
NCAV Burn Rate
-37.7%
Current Ratio
8.23
Debt/Equity
0.0
EV/REV
0.35x
EV/EBIT
-0.5x
EV/FCF
-0.3x
Dilution
23.4% p.A
Total Net Income
-308.5M $
Cheapness
100.0%
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average